Meeting
2022 ASCO Genitourinary Cancers Symposium
Impact of FDA label change on immunotherapy for metastatic urothelial cancer (mUC) and subsequent changes in mortality.
Authors
Daniel Vader
University of Pennsylvania, Philadelphia, PA
Daniel Vader , Ravi Bharat Parikh , Haojie Li , Kentaro Imai , Rebecca A. Hubbard , Ronac Mamtani
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 459)
DOI
10.1200/JCO.2022.40.6_suppl.459
Abstract #
459
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Influence of first-line chemotherapy regimen on survival outcomes of patients with advanced urothelial carcinoma who receive second-line immunotherapy.
First Author: Benjamin Miron
Poster
2024 ASCO Annual Meeting
Treatment trends for metastatic urothelial carcinoma across eight Mexican centers: A global oncology perspective.
First Author: Evelyn Lilian Beas-Lozano
Poster
2023 ASCO Genitourinary Cancers Symposium
US real-world first-line (1L) treatment patterns and outcomes for patients with metastatic urothelial carcinoma (mUC) following maintenance avelumab approval.
First Author: Haojie Li
Poster
2021 Genitourinary Cancers Symposium
A phase III, randomized, open-label, multicenter, global study of first-line durvalumab plus standard of care (SoC) chemotherapy and durvalumab plus tremelimumab, and SoC chemotherapy versus SoC chemotherapy alone in unresectable locally advanced or metastatic urothelial cancer (NILE).
First Author: Matt D. Galsky